Codexis, Inc. (CDXS)
After hours:
| Previous close | 3.4000 |
| Open | 3.3800 |
| Bid | 3.4900 x 300 |
| Ask | 3.5300 x 200 |
| Day's range | 3.3800 - 3.5400 |
| 52-week range | 1.4500 - 4.9100 |
| Volume | |
| Avg. volume | 597,177 |
| Market cap | 247.657M |
| Beta (5Y monthly) | 2.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9400 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.57 |
GlobeNewswireCodexis to Participate in TD Cowen 2nd Annual Sustainability Week
REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a panel discussion titled, “Sustainable API Manufacturing” at the TD Cowen 2nd Annual Sustainability Week, being held virtually May 21-23, 2024. During the presentation, Management will highlight the potential benefits of an enzymatic route of synthesis in the manufacture of small molecule and siRNA therapeutics. The panel will
- GlobeNewswire
Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has successfully synthesized an oligonucleotide via an enzymatic route to support RNA-based therapeutics manufacturing. Data highlighting this historic manufacturing milestone are being presented today in a Spotlight Presentation at the TIDES USA annual meeting taking place in Boston, MA, and virtually May 14 – 17, 2024. “The data presented today by Codexi
Simply Wall St.Codexis First Quarter 2024 Earnings: Beats Expectations
Codexis ( NASDAQ:CDXS ) First Quarter 2024 Results Key Financial Results Revenue: US$17.1m (up 32% from 1Q 2023). Net...
